[Transcutaneous vagus nerve stimulation for primary insomnia and affective disorder:a report of 35 cases].
[Transcutaneous vagus nerve stimulation for primary insomnia and affective disorder:a report of 35 cases].
复制标题
DOI：
10.13703/j.0255-2930.2017.03.013
复制
发表时间：
2017-03-12
期刊：
影响因子：
--
通讯作者：
Rong, Peijing
中科院分区：
文献类型：
--
作者：
Luo, Man;Qu, Xiaoxiao;Rong, Peijing
目的：目的：观察和评价耳甲部经皮迷走神经刺激（taVNS）治疗原发性失眠症（PI）和情感性精神障碍的临床疗效。采用自行研制的耳迷走神经刺激器（TENS-200 A）刺激耳廓，每次30 min，2次/d，每周5 d，连续4周。在第6周末进行随访。采用睡眠质量指数量表（PSQI）、17项汉密尔顿抑郁量表（17 HAMD）和汉密尔顿焦虑量表（HAMA）进行评定。观察治疗前后PSQI、HAMA、17 HAMD评分及安全性。结果：治疗2周末PSQI评分为（13.20±3.61）分，与治疗前比较，差异有显著性（P
OBJECTIVE: To observe and evaluate the clinical efficacy of transcutaneous vagus nerve stimulation (taVNS) at auricular concha for primary insomnia (PI) and affective disorder.METHODS: A total of 35 patients who met the diagnosis standard of PI in Diagnostic and statistical manual of mental disorders (5th edition) were included. The self-developed auricular vagus nerve stimulator (TENS-200A) was applied at auricular concha, 30 min per treatment, twice a day, 5 days a week for consecutive 4 weeks. The follow-up visit was conducted at the end of 6th week. The Pittsburg sleep quality index scale (PSQI), 17-items Hamilton depression scale (17HAMD) and Hamilton anxiety scale (HAMA) were applied for evaluation. The PSQI, HAMA and 17HAMD were observed before and after treatment; the safety was also observed.RESULTS: Compared before treatment, the PSQI was significantly decreased to (13.20±3.61) at the end of 2nd week (P